SHANGHAI – Innovent Biologics Inc., an antibody-focused company based in Suzhou, is betting that the best things will come in pairs. The Chinese biopharma signed its second deal with Adimab LLC, an antibody developer based in Lebanon, N.H., this time for bispecifics. Moreover, this is Innovent's second bispecifics agreement in the span of a week, having also inked a $120 million deal with local start-up, Epimab Biotherapeutics Inc., for its DNA-based approach to bispecifics.